MBOT

Business Context and Reporting Period

Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2006
Business Overview: The Company is a biotechnology firm focused on stem cell technology for therapeutic products. It has not achieved profitability and relies on external financing, grants, and licensing revenue. In March 2006, the Company initiated a Phase I clinical trial for neuronal ceroid lipofuscinosis (NCL).

Key Financial Metrics

Cash Flow (Nine Months Ended Sep 30, 2006):
- Net cash used in operating activities: ($12,077,200)
- Net cash used in investing activities: ($1,318,929)
- Net cash provided by financing activities: $34,295,771 (Primarily from a registered direct placement of common stock).

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 80% in the third quarter and 51% for the nine months compared to 2005. This was primarily due to the completion of a Small Business Technology Transfer grant for Alzheimer's disease studies by March 31, 2006.
• Operating Expenses Increase: Total operating expenses increased 33% in the quarter and 25% for the nine months.
  • R&D: Increased 51% (quarter) and 59% (nine months) due to expansion in cell processing, clinical development, and headcount. A significant portion of the increase ($281k in Q3, $734k in 9 months) is attributable to the adoption of SFAS 123R (stock-based compensation expensing).
  • G&A: Increased 22% (quarter) and 24% (nine months), driven by personnel costs and stock-based compensation.
  • Wind-down Expenses: Decreased 43% (quarter) and 75% (nine months) as the Company adjusted reserves for its former Rhode Island facilities.
• Other Income: Total other income decreased significantly (83% in Q3, 60% in 9 months) due to the absence of a one-time $3.75 million gain from a license and settlement agreement with ReNeuron recorded in 2005. Interest income increased due to higher investment balances.
• Liquidity: Cash balances increased by approximately $20.9 million during the nine-month period, driven by a $35.8 million equity offering in April 2006.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects to incur substantial operating losses in the future. The Company does not expect to be profitable for several years and will require additional capital to fund clinical trials and product development.
• Unusual Items:
  • ReNeuron Investment: The Company holds a 7.5% equity interest in ReNeuron Group plc. The fair market value of this investment declined from approximately $3.72 million (Dec 31, 2005) to $1.04 million (Sep 30, 2006), resulting in an unrealized loss of approximately $3.04 million recorded in "Accumulated other comprehensive loss."
  • Wind-down Reserve: The Company maintains a reserve of approximately $5.65 million for lease and operating costs related to its former Rhode Island facilities. This reserve is subject to periodic adjustment based on vacancy rates and market conditions.
• Risks:
  • Capital Needs: Significant uncertainty regarding the availability of future financing.
  • Clinical Trials: Risks associated with the Phase I NCL trial, including delays, unanticipated costs, or lack of efficacy.
  • Intellectual Property: Ongoing patent oppositions by Geron Corporation in Europe and a lawsuit filed by StemCells against Neuralstem, Inc. in the U.S.
  • Facility Obligations: Continued obligation to pay lease costs for Rhode Island facilities despite efforts to sublease or sell.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $55.4 million cash balance against the projected burn rate, given the expectation of continued losses and the need for future financing.
• ReNeuron Valuation: Assess the risk of the $3.04 million unrealized loss on the ReNeuron investment becoming realized if the decline is deemed "other than temporary."
• Rhode Island Liability: Monitor the "Accrued wind-down expenses" reserve ($6.88 million total liability) and the Company's ability to sublease the facility to reduce this burden.
• Stock-Based Compensation: Review the impact of SFAS 123R adoption on future earnings, noting approximately $7.31 million of unrecognized stock option expense remaining.
• Legal Proceedings: Track the status of the patent opposition by Geron Corporation and the lawsuit against Neuralstem, Inc., as outcomes could materially affect IP rights.